Recursion Pharmaceuticals Inc. (RXRX), which recently merged with Exscientia to advance the industrialization of drug discovery, has several key catalysts to watch for in the coming months.
The two companies, which operate in the AI drug discovery space, completed the business combination as recently as Nov.20, 2024.
The combined company has more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs, and over $450 million in upfront and realized milestone payments received from partners to date out of a potential total of more than $20 billion.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.